{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:49:33Z","timestamp":1784836173515,"version":"3.55.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K15693"],"award-info":[{"award-number":["22K15693"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jns.2023.120811","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T22:00:40Z","timestamp":1694815240000},"page":"120811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Switching between anti-calcitonin gene-related peptide monoclonal antibodies: A comparison of monthly and quarterly dosing"],"prefix":"10.1016","volume":"453","author":[{"given":"Keiko","family":"Ihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiya","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Takizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.jns.2023.120811_bb0005","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.jns.2023.120811_bb0010","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial","volume":"38","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia"},{"issue":"19","key":"10.1016\/j.jns.2023.120811_bb0015","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1001\/jama.2018.4853","article-title":"Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial","volume":"319","author":"Dodick","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jns.2023.120811_bb0020","article-title":"Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: A phase 2 randomized controlled clinical trial","volume":"3","author":"Sakai","year":"2020","journal-title":"Cephalalgia. Rep."},{"issue":"7","key":"10.1016\/j.jns.2023.120811_bb0025","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/head.14178","article-title":"Efficacy and safety of fremanezumab for episodic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients","volume":"61","author":"Sakai","year":"2021","journal-title":"Headache"},{"issue":"6","key":"10.1016\/j.jns.2023.120811_bb0030","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/head.14138","article-title":"Erenumab treatment for migraine prevention in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study","volume":"61","author":"Takeshima","year":"2021","journal-title":"Headache"},{"issue":"5","key":"10.1016\/j.jns.2023.120811_bb0035","doi-asserted-by":"crossref","DOI":"10.1177\/03331024231177649","article-title":"Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: a 12-month, single-center, observational real-world study in Japan","volume":"43","author":"Suzuki","year":"2023","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.jns.2023.120811_bb0040","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1186\/s12883-022-03041-1","article-title":"Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis","volume":"22","author":"Takizawa","year":"2022","journal-title":"BMC Neurol."},{"issue":"4","key":"10.1016\/j.jns.2023.120811_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/ejhpharm-2021-002946","article-title":"Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series","volume":"30","author":"Brice\u00f1o-Casado","year":"2023","journal-title":"Eur. J. Hosp. Pharm."},{"issue":"4\u20135","key":"10.1016\/j.jns.2023.120811_bb0050","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/03331024211048765","article-title":"Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study","volume":"42","author":"Overeem","year":"2022","journal-title":"Cephalalgia"},{"issue":"8","key":"10.1016\/j.jns.2023.120811_bb0055","first-page":"638","article-title":"Failure of monoclonal antibodies against CGRP or its receptor does not imply lack of efficacy of other drugs from the same class","volume":"36","author":"Porta-Etessam","year":"2021","journal-title":"Neurol. (Engl Ed)"},{"issue":"2","key":"10.1016\/j.jns.2023.120811_bb0060","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/head.13729","article-title":"Non-responders to treatment with antibodies to the CGRP-receptor may profit from a switch of antibody class","volume":"60","author":"Ziegeler","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.jns.2023.120811_bb0065","doi-asserted-by":"crossref","first-page":"1154420","DOI":"10.3389\/fneur.2023.1154420","article-title":"Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: a real-world cohort study","volume":"14","author":"Overeem","year":"2023","journal-title":"Front. Neurol."},{"issue":"4","key":"10.1016\/j.jns.2023.120811_bb0070","doi-asserted-by":"crossref","DOI":"10.1177\/03331024231160519","article-title":"Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: a retrospective cohort study","volume":"43","author":"Iannone","year":"2023","journal-title":"Cephalalgia"},{"issue":"1","key":"10.1016\/j.jns.2023.120811_bb0075","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12883-023-03203-9","article-title":"Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an Austrian case series","volume":"23","author":"Kaltseis","year":"2023","journal-title":"BMC Neurol."},{"issue":"1","key":"10.1016\/j.jns.2023.120811_bb0080","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s10194-019-0998-8","article-title":"Physician and patient preferences for dosing options in migraine prevention","volume":"20","author":"Cowan","year":"2019","journal-title":"J. Headache Pain"},{"issue":"1","key":"10.1016\/j.jns.2023.120811_bb0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s10194-023-01556-7","article-title":"Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-Centre retrospective observational study","volume":"24","author":"Ihara","year":"2023","journal-title":"J. Headache Pain"},{"issue":"1","key":"10.1016\/j.jns.2023.120811_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition","volume":"38","year":"2018","journal-title":"Cephalalgia"},{"issue":"5","key":"10.1016\/j.jns.2023.120811_bb0095","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1212\/CPJ.0000000000000774","article-title":"Improving access to care for patients with migraine in a remote Pacific population","volume":"10","author":"Baker","year":"2020","journal-title":"Neurol. Clin. Pract."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X23002721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X23002721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:03:48Z","timestamp":1758384228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X23002721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":19,"alternative-id":["S0022510X23002721"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2023.120811","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching between anti-calcitonin gene-related peptide monoclonal antibodies: A comparison of monthly and quarterly dosing","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2023.120811","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120811"}}